1Gotto A, Pownall H. Lipid - Regulation Drugs and Low - Density Lipoprotein Aaph - eresis Gotto A, Pownall H, Eds. Manual of Lipid Disorders. 2eded. Lippincott Williams & Wilkins, 1999. 292 ～ 328
2Bakker- Arkema RG, Davidson MH, Coldstein RJ, et al. Efficacy and safety of a new HMG - GoAreductase inhibitor, atrovastatin, in patients with hypertrigl yceridemia JAMA, 1996,275 (2): 128 ～ 133
3Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atrovastatin versus simvastatin, pravastatin, lovastatin, and fiuvastatin in patients with hypercholesterolemia (the CUPVES study). Am J Cardiol, 1998,81(5) :582 ～ 587
4Guan Y, Breyer MD. Peroxisome oroliferator - activated receptors (PPARs) :Novel theraputic targets in renal disease. Kidney Int,2001,60(1):14～30
5Taelsb, Dallongville J, Auwerx J,et al. Mechaniams of action of fibrate on lipid and lipoprotein metabolism. Circulation, 1998, 98 ( 19 ): 2088 ～ 2093
6Ruotolo G, Ericsson CG, Tettarmanti C, et al. Treatment effect on serumlipoprotine lipids, apolipoproteins and low density liporotine particle size and relationships of lipoprotine variables to progression of coronary artery disease in the Bezafibrate Cotonary Atherosclerosis Intervention Trial(BECAIT) [ J]. J Am Coll Cardiol, 1998,32:1648
7Morgan JM. Treamant and Effect of Niaspan, a Controlled - release Niacin,in Patients with Hypercholes terolemia is A Plcebo- controlled Trial.J Cardiovase Pharmacol Ther, 1996, (3): 195 ～ 202
8陈嘉新 韦永岩.高血脂血症的药物治疗新进展[J].药师通讯,1996,1:11-11.
9周自水,王世翔.新编常用药物手册,第3版,1998:278
10Texje R, Pedersen MD, Anders G, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the 4s. Circulation, 1998,97(15): 1453
